MENU
+Compare
ESPR
Stock ticker: NASDAQ
AS OF
Jul 28, 04:59 PM (EDT)
Price
$1.60
Change
+$0.09 (+5.96%)
Capitalization
495.94M

ESPR Esperion Therapeutics Forecast, Technical & Fundamental Analysis

Esperion Therapeutics Inc is a pharmaceutical company... Show more

Industry: #Biotechnology
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ESPR with price predictions
Jul 25, 2025

ESPR in +13.53% Uptrend, rising for three consecutive days on July 25, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ESPR advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on ESPR as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ESPR just turned positive on July 22, 2025. Looking at past instances where ESPR's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 46 cases where ESPR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ESPR broke above its upper Bollinger Band on July 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (63.038). P/E Ratio (0.000) is within average values for comparable stocks, (88.783). ESPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (2.473) is also within normal values, averaging (18.474).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ESPR is expected to report earnings to fall 31.29% to -14 cents per share on August 05

Esperion Therapeutics ESPR Stock Earnings Reports
Q2'25
Est.
$-0.14
Q1'25
Missed
by $0.05
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.03
Q2'24
Missed
by $0.17
The last earnings report on May 06 showed earnings per share of -20 cents, missing the estimate of -15 cents. With 6.23M shares outstanding, the current market capitalization sits at 495.94M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3891 Ranchero Drive
Phone
+1 734 887-3903
Employees
240
Web
https://www.esperion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSEFX14.790.06
+0.41%
Royce Small-Cap Special Equity Svc
NELAX61.790.22
+0.36%
Nuveen Equity Long/Short A
PHPIX24.200.02
+0.08%
ProFunds Pharmaceuticals UltraSector Inv
MXIVX15.280.01
+0.07%
Empower International Value Inv
JNEMX22.44-0.06
-0.27%
JPMorgan International Equity R6

ESPR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with ALKS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then ALKS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+1.34%
ALKS - ESPR
35%
Loosely correlated
-1.51%
DVAX - ESPR
33%
Loosely correlated
+1.79%
AQST - ESPR
30%
Poorly correlated
-1.19%
AMPH - ESPR
29%
Poorly correlated
-1.15%
ANIP - ESPR
28%
Poorly correlated
+1.06%
More